Sai Parenterals Limited (NSE: SAIPARENT) has announced its un-audited financial results for the quarter and half-year ended 30th September 2026, showcasing significant growth and strategic advancements. Revenue from operations stood at Rs. 196.1 crore, up 9.0% quarter-over-quarter (QoQ) from Rs. 179.9 crore in Q1FY27. The first half of FY27 revenue of Rs. 376.0 crore represents approximately 50% of the FY27 revenue target of Rs. 750 crore, ahead of the guided 45:55 phasing between the two halves.

Key Financial Highlights

Gross profit stood at Rs. 93.1 crore, up 26.4% QoQ, with gross margin rising to 47.5% from 40.9% in Q1FY27. The improvement reflects tighter inventory management: higher-cost inventory from earlier periods was consumed, and first-in, first-out controls were introduced on a new ERP system. EBITDA stood at Rs. 41.4 crore, up 67.4% QoQ, with EBITDA margin at 21.1% against 13.7% in Q1FY27. Despite a more than threefold sequential rise in depreciation, PAT grew 32.7% QoQ to Rs. 10.5 crore in Q2FY27.

Strategic Developments

Following shareholders’ approval of the variation in the objects of the issue, the Company has completed the acquisition of 60% stakes in Saicriti Pharma Private Limited and Prathyak Laboratories Private Limited. It invested Rs. 98.8 crore of IPO proceeds: Rs. 83.83 crore in Saicriti and Rs. 15 crore in Prathyak. The purpose for which the IPO funds were raised remains unchanged: EU-GMP compliant injectable capacity for regulated markets, and a dedicated research and development platform.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sai Parenterals Limited

Sai Parenterals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Sai falls 12.4% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at 126.1% and profits at 111.8% CAGR. Both numbers are exceptional. The stock holds at 28% of its 52-week range with RSI at 40. In other words, neither side has a clear edge right now. Revenue grows at 126.1% and profits at 111.8% CAGR, with D/E of 0.00. Meanwhile, the stock dips 12.4% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sai Parenterals Limited.

Rainbow Childrens Medicare Limited (RAINBOW) has announced its Q2FY27 earnings, showcasing a robust performance with a 23% increase in revenue and an 11% rise in PAT. The focus keyword, ‘Rainbow Childrens Medicare Limited RAINBOW Q2FY27 Earnings,’ encapsulates the essence of this financial update.

Operational Highlights

The company’s operational KPIs reflect significant growth. Notably, the number of IP discharges increased by 19% in Q2FY27 compared to the same period last year. Additionally, the occupancy rate saw a 10% rise, indicating higher utilization of hospital capacity. The average revenue per occupied bed (ARPOB) remained stable, underscoring efficient cost management.

Financial Performance

In terms of financial performance, Rainbow Childrens Medicare Limited’s EBITDA grew by 14% year-on-year, driven by strong operational efficiencies and strategic expansions. The EBITDA margin improved slightly, reflecting better cost control and operational leverage.

Forward-Looking Statement

Looking ahead, Rainbow Childrens Medicare Limited remains optimistic about its growth trajectory, with plans for further expansion and capacity enhancement in its existing and new hospitals. The company is committed to maintaining its high standards of healthcare delivery while exploring new avenues for growth and innovation.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Rainbow Childrens Medicare Limited

Rainbow Childrens Medicare Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Rainbow falls 16.4% over three months and has not found a floor yet. The PEG stands at 4.58 — severely stretched. Any earnings miss could trigger a sharp de-rating. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock holds at 31% of its 52-week range with RSI at 34. In other words, neither side has a clear edge right now. Revenue grows at 13.1% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Rainbow Childrens Medicare Limited.

Narayana Hrudayalaya Limited, a leading healthcare service provider, announced its financial results for the second quarter (Q2 FY27) ended September 30th, 2026. The company reported consolidated operating revenue of ₹ 28,440 Mn, marking a year-on-year growth of 73.0%. The earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at ₹ 6,054 Mn, up 42.0% YoY.

Strong Earnings Growth

The consolidated EBITDA rose 42.0% year-on-year and 19.8% quarter-on-quarter to ₹ 6,054 Mn, while the profit after tax (PAT) increased by 16.6% YoY and 45.3% QoQ to ₹ 3,012 Mn. Excluding the UK, revenue grew 22.6% YoY to ₹ 20,156 Mn and EBITDA grew 27.8% to ₹ 5,452 Mn, with the margin expanding to 27.0% from 25.9%.

India – Volume, Mix and Margin Expansion

India revenue grew 16.6% YoY, driven by higher patient volumes, complex procedures and a 75.7% rise in international patient revenue; India hospitals EBITDA margin expanded to 26.8% from 23.8% a year ago.

Forward-Looking Statement

With a strong first half behind us, we thank the investor community for their continued faith and remain confident of delivering on our expectations for the year, said Dr. Emmanuel Rupert, Managing Director and Group CEO, Narayana Hrudayalaya Limited.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Narayana Hrudayalaya Ltd.

Narayana Hrudayalaya Ltd. belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Narayana falls 15.3% over three months and has not found a floor yet. The PEG stands at 4.29 — severely stretched. Any earnings miss could trigger a sharp de-rating. Thin margins at 9.0% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock holds at 26% of its 52-week range with RSI at 38. In other words, neither side has a clear edge right now. Revenue grows at 20.5% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Narayana Hrudayalaya Ltd..